35
Participants
Start Date
November 13, 2008
Primary Completion Date
March 19, 2012
Study Completion Date
February 13, 2015
ridaforolimus
oral ridaforolimus 40 mg days 1-5 each week (once daily for 5 consecutive days every week; cycle arbitrarily defined as a 4 week period)
gene expression analysis
immunohistochemistry staining method
laboratory biomarker analysis
Tom Baker Cancer Centre, Calgary
Cross Cancer Institute, Edmonton
BCCA - Cancer Centre for the Southern Interior, Kelowna
BCCA - Fraser Valley Cancer Centre, Surrey
Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton
Cancer Centre of Southeastern Ontario at Kingston, Kingston
London Regional Cancer Program, London
Univ. Health Network-Princess Margaret Hospital, Toronto
CHUM - Hopital Notre-Dame, Montreal
McGill University - Dept. Oncology, Montreal
Allan Blair Cancer Centre, Regina
Lead Sponsor
Collaborators (1)
Ariad Pharmaceuticals
INDUSTRY
NCIC Clinical Trials Group
NETWORK